<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Clin Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Int J Clin Oncol</journal-id><journal-title-group><journal-title>International Journal of Clinical Oncology</journal-title></journal-title-group><issn pub-type="ppub">1341-9625</issn><issn pub-type="epub">1437-7772</issn><publisher><publisher-name>Springer Nature Singapore</publisher-name><publisher-loc>Singapore</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39630213</article-id><article-id pub-id-type="pmc">PMC11785691</article-id>
<article-id pub-id-type="publisher-id">2656</article-id><article-id pub-id-type="doi">10.1007/s10147-024-02656-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Discovery and validation of Hsa-microRNA-3665 promoter methylation as a potential biomarker for the prognosis of esophageal squaous cell carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhou</surname><given-names>Jinsong</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Liu</surname><given-names>Shuang</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Juwei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zeng</surname><given-names>Qiaoyan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Zheng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Fu</surname><given-names>Rong</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Yulan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1334-5334</contrib-id><name><surname>Hu</surname><given-names>Zhijian</given-names></name><address><email>huzhijian@fjmu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/050s6ns64</institution-id><institution-id institution-id-type="GRID">grid.256112.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1797 9307</institution-id><institution>Department of Epidemiology and Health Statistics, School of Public Health, </institution><institution>Fujian Medical University, </institution></institution-wrap>1 Xue Yuan Road, University Town, Fuzhou, 350122 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0400g8r85</institution-id><institution-id institution-id-type="GRID">grid.488530.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 1803 6191</institution-id><institution>Sun Yat-Sen University Cancer Center/Cancer Hospital, </institution></institution-wrap>Guangzhou, 510060 China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/050s6ns64</institution-id><institution-id institution-id-type="GRID">grid.256112.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1797 9307</institution-id><institution>Key Laboratory of Ministry of Education for Gastrointestinal Cancer, </institution><institution>Fujian Medical University, </institution></institution-wrap>Fuzhou, 350108 China </aff></contrib-group><pub-date pub-type="epub"><day>4</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>4</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>30</volume><issue>2</issue><fpage>309</fpage><lpage>319</lpage><history><date date-type="received"><day>5</day><month>3</month><year>2024</year></date><date date-type="accepted"><day>3</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Methylation of microRNA (miRNA) promoters associated with diseases is a common epigenetic mechanism in the development of various human cancers. However, its relationship with prognosis in esophageal squamous cell carcinoma (ESCC) remains unclear. This study aims to explore the association between the methylation level of has-miR-3665 promoter and prognosis in ESCC.</p></sec><sec><title>Methods</title><p id="Par2">Human miRNA data were downloaded from miRbase, and we identified CpG islands of these human miRNAs by genomics browser analysis. MiRNA methylation levels were detected by methylation-specific high-resolution melting. Gene ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were used to explore the molecular mechanism of hsa-miR-3665. Cox regression analysis was used to investigate prognostic factors. The overall survival rate was predicted by a nomogram.</p></sec><sec><title>Results</title><p id="Par3">We found that 88 human miRNAs had promoter methylatio, of which 15 miRNAs were found to be epigenetically regulated in ESCC cells compared with their normal counterparts, including hsa-miR-3665. Meanwhile, hsa-miR-3665 expression was significantly lower in ESCC tumour tissue than in adjacent tissue (<italic>P</italic>&#x02009;=&#x02009;0.03). GO and KEGG analyses demonstrated that the target genes are involved in protein transport, transcription regulator activity, MAPK and RAS signaling pathway. High hsa-miR-3665 promoter methylation levels were associated with a poor prognosis (<italic>HR</italic>&#x02009;=&#x02009;3.89, 95% <italic>CI</italic> 1.11&#x02009;~&#x02009;13.55). Moreover, a nomogram incorporating the hsa-miR-3665 methylation level and clinical factors presented a good performance for predicting survival in the training and validation tests, with C-indices of 0.748 and 0.751, respectively.</p></sec><sec><title>Conclusions</title><p id="Par4">High hsa-miR-3665 promoter methylation levels may be a potential biomarker for the progression of ESCC.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s10147-024-02656-3.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Esophageal squamous cell carcinoma</kwd><kwd>Hsa-miR-3665</kwd><kwd>Promoter methylation</kwd><kwd>Prognosis</kwd></kwd-group><funding-group><award-group><funding-source><institution>Scientific and Technological Innovation Joint Capital Projects of Fujian Province</institution></funding-source><award-id>2020Y9018</award-id><principal-award-recipient><name><surname>Hu</surname><given-names>Zhijian</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003392</institution-id><institution>Natural Science Foundation of Fujian Province</institution></institution-wrap></funding-source><award-id>2021J01726</award-id><award-id>2021J01733</award-id><principal-award-recipient><name><surname>Lin</surname><given-names>Zheng</given-names></name><name><surname>Hu</surname><given-names>Zhijian</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Central government-led local science and technology development special project</institution></funding-source><award-id>2020L3009</award-id><award-id>2019L3006</award-id><principal-award-recipient><name><surname>Hu</surname><given-names>Zhijian</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Japan Society of Clinical Oncology 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par19">Esophageal cancer, a global public health problem, is one of the most common digestive system cancers around the world [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Esophageal squamous cell carcinoma (ESCC) is the predominant type of esophageal cancer in China [<xref ref-type="bibr" rid="CR3">3</xref>]. Although the available treatment has improved recently, the prognosis of ESCC remains unsatisfactory [<xref ref-type="bibr" rid="CR4">4</xref>]. An increasing number of studies evaluating miRNA expression in regard to ESCC prognosis have been reported [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]; however, only a few studies have explored the association between miRNA promoter methylation and ESCC prognosis.</p><p id="Par20">DNA methylation is a well-established epigenetic mechanism critical for cancer, and it mainly occurs in CpG islands [<xref ref-type="bibr" rid="CR7">7</xref>]. It has been considered a potential biomarker for cancers [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. MiRNAs are the most widely described ncRNAs, and researchers have shown that miRNAs could play significant roles in many biological processes, including cellular development, differentiation, invasion, etc. [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Studies have reported that miRNA genes have CpG islands in their promoter regions, which could be affected by methylation [<xref ref-type="bibr" rid="CR12">12</xref>]. In fact, approximately 20% of all miRNAs are embedded within CpG islands [<xref ref-type="bibr" rid="CR13">13</xref>]. In recent studies, it was revealed that epigenetic alterations were associated with the dysregulation of miRNAs in cancers. For instance, Gao et al. [<xref ref-type="bibr" rid="CR14">14</xref>] pointed out that miR-145-5p promoter hypermethylation inhibited miR-145-5p expression through epigenetic inactivation and low miR-145-5p expression was associated with a worse prognosis in laryngeal squamous cell carcinoma. Similarly, in prostate cancer, significantly higher miR-34 methylation levels independently predicted a shorter disease-free survival [<xref ref-type="bibr" rid="CR15">15</xref>]. These studies demonstrated that miRNA promoter methylation is a significant predictor of patient outcomes. For ESCC, there are two studies indicated hypermethylation-mediated inactivation of miR-124, miR-203a and miR-203b may be useful for a poor prognostic marker for ESCC patients [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. However, these studies did not systematically screen for human miRNA promoter methylation and focused only on specific miRNAs promoter methylation. Hence, studies comprehensively exploring miRNA promoter methylation profiles in regards to the ESCC prognosis are necessary.</p><p id="Par21">MiR-3665 was initially recognized for its role in neurodevelopment, where it influences neurodevelopmental injuries and cognitive disorders [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. It is also linked to aging and rejuvenation [<xref ref-type="bibr" rid="CR19">19</xref>]. Research has demonstrated that miR-3665 influences immune system function in lung cancer by targeting the COL1A1 and COL5A1 genes [<xref ref-type="bibr" rid="CR20">20</xref>]. Furthermore, in endometrial cancer, miR-3665 is downregulated due to promoter hypermethylation [<xref ref-type="bibr" rid="CR21">21</xref>]. However, the role of miR-3665 promoter methylation in ESCC remains unclear. Elucidating the relationship between miR-3665 and prognosis in ESCC could help identify a new potential biomarker.</p><p id="Par22">In this study, we downloaded human miRNA data from miRbase and identified the CpG islands of these human miRNAs using several genomics browser analyses. Furthermore, eighty-eight miRNA promoter methylation sites were verified in ESCC cell lines by using miProfileTM miRNA qPCR microarray technology. Then, the ESCC tumour tissue miRNA methylation level was detected by methylation-specific high-resolution melting. Here, we found that high hsa-miR-3665 promoter methylation levels in ESCC patients were significantly correlated with a worse prognosis. The hsa-miR-3665 promoter methylation levels may be potentially useful as a novel biomarker for ESCC prognosis.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Human miRNAs sources download</title><p id="Par23">The hairpin and mature sequences of miRNA were identified in the miRBase database. In addition, all sequence and annotation data are also available for download. We downloaded the human miRNA data through miRBase (<ext-link ext-link-type="uri" xlink:href="http://www.mirbase.org/">http://www.mirbase.org/</ext-link>, version 18.0).</p></sec><sec id="Sec4"><title>The CpG islands of miRNAs analysis</title><p id="Par24">We identified CpG islands of these human miRNAs using several genomics browser analyses, such as the UCSC Genome Browser (<ext-link ext-link-type="uri" xlink:href="http://genome.ucsc.edu/">http://genome.ucsc.edu/</ext-link>), CpG Island Searcher (<ext-link ext-link-type="uri" xlink:href="http://www.cpgislands.com/">http://www.cpgislands.com/</ext-link>), and the European Bioinformatics Institute (EBI, <ext-link ext-link-type="uri" xlink:href="http://www.ebi.ac.uk/Tools/emboss/cpgplot/">http://www.ebi.ac.uk/Tools/emboss/cpgplot/</ext-link>). In this study, the threshold criteria for CpG islands of miRNAs were as follows: (1) UCSC Genome Browser: GC%&#x02009;&#x02265;&#x02009;50%, length&#x02009;&#x0003e;&#x02009;200&#x000a0;bp, Obs/Exp CpG&#x02009;&#x0003e;&#x02009;0.6. (2) CpG Island Searcher: GC%&#x02009;=&#x02009;60%, ObsCpG/ExpCpG&#x02009;=&#x02009;0.7, length&#x02009;=&#x02009;300&#x000a0;bp, gap between adjacent islands&#x02009;=&#x02009;100&#x000a0;bp. (3) EBI: Obs/Exp&#x02009;=&#x02009;0.7, MinPC&#x02009;=&#x02009;60, Length&#x02009;=&#x02009;300. We excluded miRNAs located on the X chromosome, and for two miRNAs with similar positions, we chose miRNAs with a large ObsCpG/ExpCpG value. To improve the accuracy of the CpG islands of prediction, we chose an intersection among the three databases.</p></sec><sec id="Sec5"><title>Cell culture</title><p id="Par25">Het-1A, Eca109, TE-1, CaES-17 and EC9706 cells were obtained from the Shanghai Institute of Biochemistry and Cell Biology and were cultured in Dulbecco's modified Eagle's medium (Sigma, USA) supplemented with 10% foetal bovine serum (FBS) (HyClone, USA). The cells were cultured at 37&#x000a0;&#x000b0;C in a humidified 5% CO2 incubator (Thermo, USA).</p></sec><sec id="Sec6"><title>Cell treatment</title><p id="Par26">To estimate the role of epigenetic mechanisms in miRNAs, 5-aza-2'-deoxycytidine (DAC) was used as follows. Two groups were created: ESCC cell lines vs. the Het-1A cell line and ESCC cell lines with 5-aza-2&#x002b9;-deoxycytidine vs. ESCC cell lines without 5-aza-2 &#x002b9; -deoxycytidine. The cells were treated with 1&#x000a0;&#x003bc;M 5-aza-dC for 72&#x000a0;h. After incubation, the cell miRNAs were isolated using the Total TRIzol Reagent Kit (Life Technologies, America). The relative quantifications of the miRNAs between the ESCC and Het-1A cell lines and between the ESCC cell lines with DAC and without DAC were detected by real-time RT-PCR (qPCR), and miProfileTM miRNA qPCR microarray technology was used. U6, U44, U48 and U47 snRNAs were used as internal controls, and the premier sequences of the miRNAs and controls are presented in Table <xref rid="MOESM1" ref-type="media">S1</xref>. Additionally, we used a reverse transcription control, a positive PCR control, and a no template control. miRNAs with fold changes (ESCC cell lines vs. Het-1A cell line)&#x02009;&#x0003c;&#x02009;0.5 and fold changes (ESCC cell lines with DAC vs. ESCC cell lines without DAC)&#x02009;&#x0003e;&#x02009;2 were screened.</p></sec><sec id="Sec7"><title>Clinical samples and follow-up</title><p id="Par27">We conducted a study of patients newly diagnosed with ESCC at the Zhangzhou Affiliated Hospital of Fujian Medical University in Fujian, China, from December 1, 2012, to August 31, 2014. Participants who underwent surgery at Zhangzhou Affiliated Hospital of Fujian Medical University were recruited. The diagnosis was confirmed by two pathologists. Patients with other cancers were excluded. Before the patients underwent surgical excision, they did not receive chemotherapy or radiotherapy. A total of 145 ESCC tissues were collected. This study was approved by the Institutional Review Boards of Fujian Medical University (NO. 2,011,052), and all participants signed informed consent forms.</p></sec><sec id="Sec8"><title>MiRNAs extraction</title><p id="Par28">MiRNAs were extracted from cells using the Total TRIzol Reagent Kit (Life Technologies, America). A NanoDrop ND-1000 system (NanoDrop, Thermo, America) was used to detect the concentration of all RNA samples.</p></sec><sec id="Sec9"><title>Quantitative real-time PCR</title><p id="Par29">To validate the miRNA expression levels, qPCR was performed using an SYBR kit (Takara, Japan) on a 7500 PCR System (Applied Biosystems, Thermo, America). The premier for the candidate miRNAs and internal controls were purchased from Guangzhou Funeng (Guangzhou, China). Table <xref rid="MOESM1" ref-type="media">S1</xref> shows the premier sequences. The 2<sup>&#x02212;&#x00394;&#x00394;CT</sup> method was applied to calculate the relative expression values for the target miRNA, which were normalized to the internal control.</p></sec><sec id="Sec10"><title>Methylation-specific high-resolution melting (MS-HRM) analyses</title><p id="Par30">Genomic DNA was extracted from ESCC tissue specimens using an adsorption column. Tissue DNA was treated with bisulfite using an EpiTect PLUS DNA Bisulfite kit (QiaGen, Germany) according to the manufacturer&#x02019;s protocol. Methylation-sensitive high-resolution melting (MS-HRM) assays were used to detect the methylation levels. Briefly, bisulfite-modified unmethylated and methylated standard DNA (Qiagen GmbH) was mixed, giving the samples 0, 25, 50, 75, and 100% methylation degrees for calibration. A standard curve with known methylation degrees was included in each run. The hsa-miR-3665 premier sequence is listed in Table <xref rid="MOESM2" ref-type="media">S2</xref>. The hsa-miR-3665 amplification conditions were 39 cycles at 95&#x000a0;&#x000b0;C for 30&#x000a0;s, 56.7&#x000a0;&#x000b0;C for 30&#x000a0;s and 72&#x000a0;&#x000b0;C for 15&#x000a0;s. High-resolution melting analysis with LightScanner TM was used to analyse the products after PCR. The HRM data were calculated using High-Resolution Melting Software version 2.0.1 (Applied Biosystems). We divided 145 ESCC patients into two groups according to their 50% methylation levels.</p></sec><sec id="Sec11"><title>Prediction of target genes of hsa-miR-3665</title><p id="Par31">The target genes of hsa-miR-3665 were predicted using the following miRPathDB (<ext-link ext-link-type="uri" xlink:href="https://mpd.bioinf.uni-sb.de/overview.html">https://mpd.bioinf.uni-sb.de/overview.html</ext-link>), miRWalk (<ext-link ext-link-type="uri" xlink:href="http://mirwalk.umm.uni-heidelberg.de/">http://mirwalk.umm.uni-heidelberg.de/</ext-link>) and TargetScan (<ext-link ext-link-type="uri" xlink:href="http://www.targetscan.org/index.html">http://www.targetscan.org/index.html</ext-link>). The intersection of these three software results was used as the final target gene of hsa-miR-3665.</p></sec><sec id="Sec12"><title>GO and KEGG pathway enrichment analysis of target genes</title><p id="Par32">To analyze the functions of the predicted target genes of hsa-miR-3665, Gene Ontology (GO) (<ext-link ext-link-type="uri" xlink:href="http://www.geneontology.org">http://www.geneontology.org</ext-link>) was used for gene functional enrichment of predicted target genes. Kyoto Encyclopedia of Genes and Genomes (KEGG) data (<ext-link ext-link-type="uri" xlink:href="http://www.kegg.jp/kegg/">http://www.kegg.jp/kegg/</ext-link>) was used for analyzing the roles of target genes. The human genome was used as a genetic background. <italic>P</italic> value&#x02009;&#x0003c;&#x02009;0.05 was considered statistically significant in GO terms and KEGG pathways.</p></sec><sec id="Sec13"><title>Statistical analysis</title><p id="Par33">The paired sample t-test was applied to evaluate the miRNA expression level between tumour tissue and the corresponding adjacent tissues. The association between the methylation ratio of miRNAs and the clinical factors was assessed using Chi-square test and multivariate logistic regression. Cox proportional hazard regression was used to investigate the prognostic factors for ESCC. All of the participants were randomly divided into either the training or validation set (the split ratio was 2:1), with the training and validation sets being used to establish the predictive model and to construct the nomogram [<xref ref-type="bibr" rid="CR22">22</xref>]. The C-indices and calibration curves were created to determine whether the predicted survival and actual survival were in concordance. All statistical analyses and visualizations were performed using R software (version 4.1.2). Differences were identified as considered statistically significant for two-sided <italic>P</italic> values&#x02009;&#x0003c;&#x02009;0.05.</p></sec></sec><sec id="Sec14"><title>Results</title><sec id="Sec15"><title>Screening the CpG islands of miRNAs</title><p id="Par34">In the preliminary screening, a total of 1,527 human miRNA datasets were downloaded from miRbase. The CpG islands of 1,527 miRNAs were predicted by bioinformatics methods, including the UCSC Genome Browser, CpG Island Searcher and European Bioinformatics Institute website. In this study, 88 miRNA promoter methylations were selected at a common intersection among the three databases (Table <xref rid="MOESM3" ref-type="media">S3</xref>). We also used the miProfileTM miRNA qPCR microarray of ESCC cell lines (tumour cell lines vs. the Het-1A cell line; tumour cell lines with DAC vs. tumour cell lines without DAC). Screening of candidate miRNAs was conducted according to the relative quantification (RQ) of the ESCC cells with and without DAC treatment&#x02009;&#x0003e;&#x02009;2 times and the RQ of ESCC cells and normal esophageal squamous epithelial cells&#x02009;&#x0003c;&#x02009;0.5 times and the results showed that 15 miRNAs might have differential promoter methylation in ESCC (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). The flowchart of screening the 15 miRNAs from the 1527 miRNAs is presented in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Candidate miRNAs screened in ESCC cell lines</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">No</th><th align="left">miRNAs</th><th align="left">RQ(CC vs NC)*</th><th align="left">RQ(DAC vs DMSO)*</th></tr></thead><tbody><tr><td align="left">1</td><td align="left">hsa-miR-9-5p</td><td char="." align="char">0.005</td><td char="." align="char">17.563</td></tr><tr><td align="left">2</td><td align="left">hsa-miR-203</td><td char="." align="char">0.128</td><td char="." align="char">3.535</td></tr><tr><td align="left">3</td><td align="left">hsa-miR-375</td><td char="." align="char">0.182</td><td char="." align="char">2.010</td></tr><tr><td align="left">4</td><td align="left">hsa-miR-1258</td><td char="." align="char">0.449</td><td char="." align="char">2.458</td></tr><tr><td align="left">5</td><td align="left">hsa-miR-1914-5p</td><td char="." align="char">0.116</td><td char="." align="char">2.656</td></tr><tr><td align="left">6</td><td align="left">hsa-miR-3665</td><td char="." align="char">0.206</td><td char="." align="char">2.896</td></tr><tr><td align="left">7</td><td align="left">hsa-miR-4470</td><td char="." align="char">0.251</td><td char="." align="char">3.215</td></tr><tr><td align="left">8</td><td align="left">hsa-miR-4479</td><td char="." align="char">0.107</td><td char="." align="char">3.411</td></tr><tr><td align="left">9</td><td align="left">hsa-miR-4530</td><td char="." align="char">0.158</td><td char="." align="char">3.383</td></tr><tr><td align="left">10</td><td align="left">hsa-miR-4634</td><td char="." align="char">0.467</td><td char="." align="char">3.137</td></tr><tr><td align="left">11</td><td align="left">hsa-miR-4664-5p</td><td char="." align="char">0.220</td><td char="." align="char">7.804</td></tr><tr><td align="left">12</td><td align="left">hsa-miR-4665-5p</td><td char="." align="char">0.284</td><td char="." align="char">7.364</td></tr><tr><td align="left">13</td><td align="left">hsa-miR-4674</td><td char="." align="char">0.356</td><td char="." align="char">3.342</td></tr><tr><td align="left">14</td><td align="left">hsa-miR-4687-5p</td><td char="." align="char">0.378</td><td char="." align="char">3.434</td></tr><tr><td align="left">15</td><td align="left">hsa-miR-4734</td><td char="." align="char">0.236</td><td char="." align="char">2.629</td></tr></tbody></table><table-wrap-foot><p>*RQ (CC vs NC) refers to the relative expression of ESCC cells relative to normal esophageal squamous epithelial cells (Het-1A cell line); RQ (DAC vs DMSO) refers to the relative expression of ESCC cells with DAC treatment versus no DAC treatment</p></table-wrap-foot></table-wrap><fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>The flowchart of screening 15 miRNAs from 1527 miRNAs</p></caption><graphic xlink:href="10147_2024_2656_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec16"><title>The expression of the fifteen miRNAs in ESCC tissue samples</title><p id="Par35">The expression levels of 15 miRNAs in ESCC were detected by qPCR. First, ten ESCC tissues were used to perform the initial verification. The relative quantification of the fifteen miRNAs between the ESCC tissues and the adjacent tissues in ten patients with ESCC was compared. The expression of the 15 miRNAs is shown in Table <xref rid="MOESM4" ref-type="media">S4</xref>. The number of patients whose miRNA expression in ESCC tissues was less than 0.5 times that of adjacent tissues was: hsa-miR-9-5p (4 cases), hsa-miR-203 (5 cases), hsa-miR-375 (6 cases), hsa-miR-1258 (2 cases), hsa-miR-1914-5p (3 cases), hsa-miR-3665 (7 cases), hsa-miR-4470 (2 cases), hsa-miR-4479 (3 cases), hsa-miR-4530 (4 cases), hsa-miR-4634 (5 cases), hsa-miR-4664-5p (3 cases), hsa-miR-4665-5p (4 cases), hsa-miR-4674 (3 cases), hsa-miR-4687-5p (5 cases) and hsa-miR-4734 (4 cases). The relative quantification of hsa-miR-3665 was significant (<italic>t</italic>&#x02009;=&#x02009;2.564, <italic>P</italic>&#x02009;=&#x02009;0.030) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Besides, there was an association between the expression level and promoter methylation status of hsa-miR-3665 in ten ESCC (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, Table <xref rid="MOESM5" ref-type="media">S5</xref>). Thus, we chose hsa-miR-3665 for further research.<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Comparison of miRNAs expression in ESCC tissues and adjacent tissues</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">miRNAs</th><th align="left" colspan="2">Normality test</th><th align="left" colspan="2">Paired sample <italic>t</italic> test</th></tr><tr><th align="left"><italic>Z</italic></th><th align="left"><italic>P</italic></th><th align="left"><italic>t</italic></th><th align="left"><italic>P</italic></th></tr></thead><tbody><tr><td align="left">hsa-miR-9-5p</td><td char="." align="char">0.608</td><td char="." align="char">0.853</td><td char="." align="char">1.212</td><td char="." align="char">0.256</td></tr><tr><td align="left">hsa-miR-203</td><td char="." align="char">0.576</td><td char="." align="char">0.895</td><td char="." align="char">&#x02212;&#x000a0;0.040</td><td char="." align="char">0.969</td></tr><tr><td align="left">hsa-miR-375</td><td char="." align="char">0.458</td><td char="." align="char">0.985</td><td char="." align="char">1.361</td><td char="." align="char">0.207</td></tr><tr><td align="left">hsa-miR-1258</td><td char="." align="char">0.744</td><td char="." align="char">0.637</td><td char="." align="char">0.758</td><td char="." align="char">0.468</td></tr><tr><td align="left">hsa-miR-1914-5p</td><td char="." align="char">0.587</td><td char="." align="char">0.880</td><td char="." align="char">0.931</td><td char="." align="char">0.376</td></tr><tr><td align="left">hsa-miR-3665</td><td char="." align="char">0.381</td><td char="." align="char">0.999</td><td char="." align="char">2.564</td><td char="." align="char">0.030</td></tr><tr><td align="left">hsa-miR-4470</td><td char="." align="char">0.671</td><td char="." align="char">0.759</td><td char="." align="char">&#x02212;&#x000a0;0.182</td><td char="." align="char">0.860</td></tr><tr><td align="left">hsa-miR-4479</td><td char="." align="char">0.508</td><td char="." align="char">0.959</td><td char="." align="char">0.659</td><td char="." align="char">0.526</td></tr><tr><td align="left">hsa-miR-4530</td><td char="." align="char">0.597</td><td char="." align="char">0.868</td><td char="." align="char">1.369</td><td char="." align="char">0.204</td></tr><tr><td align="left">hsa-miR-4634</td><td char="." align="char">0.549</td><td char="." align="char">0.924</td><td char="." align="char">1.866</td><td char="." align="char">0.095</td></tr><tr><td align="left">hsa-miR-4664-5p</td><td char="." align="char">0.476</td><td char="." align="char">0.977</td><td char="." align="char">0.063</td><td char="." align="char">0.951</td></tr><tr><td align="left">hsa-miR-4665-5p</td><td char="." align="char">0.522</td><td char="." align="char">0.948</td><td char="." align="char">0.977</td><td char="." align="char">0.354</td></tr><tr><td align="left">hsa-miR-4674</td><td char="." align="char">0.530</td><td char="." align="char">0.941</td><td char="." align="char">0.266</td><td char="." align="char">0.796</td></tr><tr><td align="left">hsa-miR-4687-5p</td><td char="." align="char">0.427</td><td char="." align="char">0.993</td><td char="." align="char">1.339</td><td char="." align="char">0.214</td></tr><tr><td align="left">hsa-miR-4734</td><td char="." align="char">0.376</td><td char="." align="char">0.999</td><td char="." align="char">&#x02212;&#x000a0;0.165</td><td char="." align="char">0.873</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec17"><title>Target prediction of hsa-miR-3665 and GO and KEGG pathway enrichment analysis</title><p id="Par36">A total of 17,835 target genes of hsa-miR-3665 were predicted by miRPathDB, miRWalk and TargetScan. And 3378 target genes were obtained from the intersection of three software predictions (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Venn plot of predicted target genes for has-miR-3665 (<bold>A</bold>); GO (<bold>B</bold>) and KEGG (<bold>C</bold>) pathway enrichment analysis of the target genes</p></caption><graphic xlink:href="10147_2024_2656_Fig2_HTML" id="MO2"/></fig></p><p id="Par37">For the 3378 target genes of hsa-miR-3665, GO term enrichment analysis was performed. The top 5 enriched GO terms from three categories are shown in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>B. For biological processes, regulation of small GTPase-mediated signal transduction (GO:0051056) and positive regulation of stress-activated MAPK cascade (GO:0032874) were significantly enriched. For cellular components, endocytic vesicle (GO:0030139) and early endosome (GO:0005769) were significantly enriched. For molecular functions, antiporter activity (GO:0015297) and actin-binding (GO:0003779) were significantly enriched. When performing the KEGG pathway enrichment analysis, 48 signaling pathways were significantly enriched with the criteria of <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05. Furthermore, MAPK signaling pathway, RAS signaling pathway and signaling pathways regulating the pluripotency of stem cells were significantly enriched (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>C).</p></sec><sec id="Sec18"><title>The association between hsa-miR-3665 expression and clinical features</title><p id="Par38">The MS-HRM assay of hsa-miR-3665 promoter methylation in ESCC tumour tissue was analysed by using standard dilutions including 0, 25, 50, 75, and 100% methylation controls (Fig. <xref rid="MOESM1" ref-type="media">S1</xref>). Hsa-miR-3665 was successfully amplified from all of the ESCC tumour tissue samples (Fig. <xref rid="MOESM2" ref-type="media">S2</xref>) and further detected according to its methylation levels. Two primer pairs were designed according to the location of the CpG islands (Sangon, Shanghai, China). Based on the promoter sequence of hsa-miR-3665, two pairs of methylation primers were designed (Table <xref rid="MOESM2" ref-type="media">S2</xref>). The location NC_000013 Chr13:77,698,530&#x02013;77698738 is named hsa-miR-3665-1, and the location NC_000013 Chr13:77,698,883&#x02013;77,699,056 is named hsa-miR-3665-2. According to the 50% methylation levels of hsa-miR-3665, 145 ESCC patients were divided into two groups. The correlation coefficient between the expression level and promoter methylation status of hsa-miR-3665 in 145 ESCC samples was 0.646 (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05). As shown in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>, we also performed comparisons of the hsa-miR-3665 methylation levels with regard to clinical factors. The hsa-miR-3665-1 methylation levels did not significantly correlate with clinical factors (<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05). However, there might be a significant association between hsa-miR-3665-2 methylation levels and TNM stage (<italic>P</italic>&#x02009;=&#x02009;0.038). To investigate this relationship, a multivariate binary logistic regression analysis was performed. The findings indicated that there was no significant association between the methylation levels of hsa-miR-3665-2 and TNM stage (<italic>OR</italic>&#x02009;=&#x02009;0.32, 95% <italic>CI</italic>: 0.09&#x02009;~&#x02009;1.15, Table S6).<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>The association between hsa-miR-3665 methylation levels and clinical factors</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Variables</th><th align="left" colspan="4">hsa-miR-3665-1</th><th align="left" colspan="4">hsa-miR-3665-2</th></tr><tr><th align="left">Low</th><th align="left">High</th><th align="left"><italic>&#x003c7;</italic><sup><italic>2</italic></sup></th><th align="left"><italic>P</italic></th><th align="left">Low</th><th align="left">High</th><th align="left"><italic>&#x003c7;</italic><sup><italic>2</italic></sup></th><th align="left"><italic>P</italic></th></tr></thead><tbody><tr><td align="left">Sex</td><td align="left"/><td align="left"/><td char="." align="char">0.119</td><td char="." align="char">0.730</td><td align="left"/><td align="left"/><td char="." align="char">0.437</td><td char="." align="char">0.508</td></tr><tr><td align="left">&#x000a0;Man</td><td align="left">14 (73.7)</td><td align="left">101 (80.2)</td><td char="." align="char"/><td char="." align="char"/><td align="left">22 (75.9)</td><td align="left">79 (81.4)</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Female</td><td align="left">5 (26.3)</td><td align="left">25 (19.8)</td><td char="." align="char"/><td char="." align="char"/><td align="left">7 (24.1)</td><td align="left">18 (18.6)</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Age(years)</td><td align="left"/><td align="left"/><td char="." align="char">0.202</td><td char="." align="char">0.653</td><td align="left"/><td align="left"/><td char="." align="char">1.197</td><td char="." align="char">0.274</td></tr><tr><td align="left">&#x000a0;&#x02009;&#x02264;&#x02009;60</td><td align="left">8 (42.1)</td><td align="left">60 (47.2)</td><td char="." align="char"/><td char="." align="char"/><td align="left">11 (37.9)</td><td align="left">48 (49.5)</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;&#x02009;&#x0003e;&#x02009;60</td><td align="left">11 (57.9)</td><td align="left">66 (52.4)</td><td char="." align="char"/><td char="." align="char"/><td align="left">18 (62.1)</td><td align="left">49 (50.5)</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">BMI</td><td align="left"/><td align="left"/><td char="." align="char">1.162</td><td char="." align="char">0.559</td><td align="left"/><td align="left"/><td char="." align="char">0.126</td><td char="." align="char">0.939</td></tr><tr><td align="left">&#x000a0;&#x02009;&#x0003c;&#x02009;18.5</td><td align="left">6 (31.6)</td><td align="left">26 (20.6)</td><td char="." align="char"/><td char="." align="char"/><td align="left">7 (24.1)</td><td align="left">21 (21.6)</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;18.5&#x02009;~&#x02009;24.9</td><td align="left">10 (52.6)</td><td align="left">73 (57.9)</td><td char="." align="char"/><td char="." align="char"/><td align="left">16 (55.2)</td><td align="left">57 (58.8)</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;&#x02009;&#x0003e;&#x02009;25</td><td align="left">3 (15.8)</td><td align="left">27 (21.4)</td><td char="." align="char"/><td char="." align="char"/><td align="left">6 (20.7)</td><td align="left">19 (19.6)</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Tumor location</td><td align="left"/><td align="left"/><td char="." align="char">0.893</td><td char="." align="char">0.345</td><td align="left"/><td align="left"/><td char="." align="char">0.648</td><td char="." align="char">0.421</td></tr><tr><td align="left">&#x000a0;Upper/middle</td><td align="left">15 (78.9)</td><td align="left">86 (68.3)</td><td char="." align="char"/><td char="." align="char"/><td align="left">22 (75.9)</td><td align="left">66 (68.0)</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Distal</td><td align="left">4 (21.1)</td><td align="left">40 (31.7)</td><td char="." align="char"/><td char="." align="char"/><td align="left">7 (24.1)</td><td align="left">31 (32.0)</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">TNM stage</td><td align="left"/><td align="left"/><td char="." align="char">2.528</td><td char="." align="char">0.112</td><td align="left"/><td align="left"/><td char="." align="char">4.308</td><td char="." align="char">0.038</td></tr><tr><td align="left">&#x000a0;I-II</td><td align="left">7 (36.8)</td><td align="left">71 (56.3)</td><td char="." align="char"/><td char="." align="char"/><td align="left">11 (37.9)</td><td align="left">58 (59.8)</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;III-IV</td><td align="left">12 (63.2)</td><td align="left">55 (43.7)</td><td char="." align="char"/><td char="." align="char"/><td align="left">18 (62.1)</td><td align="left">39 (40.2)</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Anastomotic fistula</td><td align="left"/><td align="left"/><td char="." align="char">1.815</td><td char="." align="char">0.178</td><td align="left"/><td align="left"/><td char="." align="char">0.327</td><td char="." align="char">0.568</td></tr><tr><td align="left">&#x000a0;No</td><td align="left">16 (84.2)</td><td align="left">120 (95.2)</td><td char="." align="char"/><td char="." align="char"/><td align="left">26 (89.7)</td><td align="left">92 (94.8)</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Yes</td><td align="left">3 (15.8)</td><td align="left">6 (4.8)</td><td char="." align="char"/><td char="." align="char"/><td align="left">3 (10.3)</td><td align="left">5 (5.2)</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Postoperative infection</td><td align="left"/><td align="left"/><td char="." align="char">0.007</td><td char="." align="char">0.931</td><td align="left"/><td align="left"/><td char="." align="char">0.000</td><td char="." align="char">1.000</td></tr><tr><td align="left">&#x000a0;No</td><td align="left">17 (89.5)</td><td align="left">108 (85.7)</td><td char="." align="char"/><td char="." align="char"/><td align="left">25 (86.2)</td><td align="left">83 (85.6)</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Yes</td><td align="left">2 (10.5)</td><td align="left">18 (14.3)</td><td char="." align="char"/><td char="." align="char"/><td align="left">4 (13.8)</td><td align="left">14 (14.4)</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left" colspan="2">Invades nerves or vessels</td><td align="left"/><td align="left">1.255</td><td char="." align="char">0.263</td><td char="." align="char"/><td align="left"/><td align="left">1.325</td><td char="." align="char">0.250</td></tr><tr><td align="left">&#x000a0;No</td><td align="left">8 (57.1)</td><td align="left">32 (41.0)</td><td char="." align="char"/><td char="." align="char"/><td align="left">11 (52.4)</td><td align="left">20 (37.7)</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Yes</td><td align="left">6 (42.9)</td><td align="left">46 (36.5)</td><td char="." align="char"/><td char="." align="char"/><td align="left">10 (47.6)</td><td align="left">33 (62.3)</td><td char="." align="char"/><td char="." align="char"/></tr></tbody></table></table-wrap></p></sec><sec id="Sec19"><title>Hsa-miR-3665 promoter methylation level might serve as a novel prognostic biomarker in ESCC</title><p id="Par39">The median overall survival time was 48.2&#x000a0;months, and the 1-year, 3-year and 5-year survival rates were 82.4%, 61.2%, and 51.4%, respectively. The Kaplan&#x02013;Meier method and log-rank test showed no significant difference (for hsa-miR-3665-1, <italic>P</italic>&#x02009;=&#x02009;0.291; for hsa-miR-3665&#x02013;2, <italic>P</italic>&#x02009;=&#x02009;0.657, Fig. <xref rid="MOESM3" ref-type="media">S3</xref>) in survival between the two groups.</p><p id="Par40">Cox regression was performed to evaluate the prognostic function of the hsa-miR-3665 promoter methylation level in ESCC. The results showed that patients with a high methylation level of hsa-miR-3665-1 had significantly worse survival <italic>(HR</italic>&#x02009;=&#x02009;3.89, 95% <italic>CI</italic> 1.11&#x02009;~&#x02009;13.55, Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). However, there was no association between the hsa-miR-3665-2 methylation level and OS (<italic>HR</italic>&#x02009;=&#x02009;1.27, 95% <italic>CI</italic> 0.54&#x02009;~&#x02009;3.00, Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>).<table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Univariate and multivariate analysis of overall survival in ESCC</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Variables</th><th align="left" colspan="2">Univariate</th><th align="left" colspan="2">Multivariate*</th><th align="left" colspan="2">Univariate</th><th align="left" colspan="2">Multivariate*</th></tr><tr><th align="left"><italic>HR</italic></th><th align="left">95% <italic>CI</italic></th><th align="left"><italic>HR</italic></th><th align="left">95% <italic>CI</italic></th><th align="left"><italic>HR</italic></th><th align="left">95% <italic>CI</italic></th><th align="left"><italic>HR</italic></th><th align="left">95%<italic> CI</italic></th></tr></thead><tbody><tr><td align="left">Sex</td><td char="." align="char"/><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">&#x000a0;Men</td><td char="." align="char">1.00</td><td align="left"/><td char="." align="char">1.00</td><td align="left"/><td char="." align="char">1.00</td><td align="left"/><td char="." align="char">1.00</td><td align="left"/></tr><tr><td align="left">&#x000a0;Female</td><td char="." align="char">0.65</td><td align="left">0.31&#x02009;~&#x02009;1.37</td><td char="." align="char">0.52</td><td align="left">0.21&#x02009;~&#x02009;1.29</td><td char="." align="char">0.65</td><td align="left">0.31&#x02009;~&#x02009;1.37</td><td char="." align="char">0.68</td><td align="left">0.26&#x02009;~&#x02009;1.81</td></tr><tr><td align="left">Age(years)</td><td char="." align="char"/><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">&#x000a0;&#x02009;&#x02264;&#x02009;60</td><td char="." align="char">1.00</td><td align="left"/><td char="." align="char">1.00</td><td align="left"/><td char="." align="char">1.00</td><td align="left"/><td char="." align="char">1.00</td><td align="left"/></tr><tr><td align="left">&#x000a0;&#x02009;&#x0003e;&#x02009;60</td><td char="." align="char">1.24</td><td align="left">0.73&#x02009;~&#x02009;2.11</td><td char="." align="char">1.37</td><td align="left">0.65&#x02009;~&#x02009;2.92</td><td char="." align="char">1.24</td><td align="left">0.73&#x02009;~&#x02009;2.11</td><td char="." align="char">1.03</td><td align="left">0.45&#x02009;~&#x02009;2.37</td></tr><tr><td align="left">BMI</td><td char="." align="char"/><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">&#x000a0;&#x02009;&#x0003c;&#x02009;18.5</td><td char="." align="char">1.00</td><td align="left"/><td char="." align="char">1.00</td><td align="left"/><td char="." align="char">1.00</td><td align="left"/><td char="." align="char">1.00</td><td align="left"/></tr><tr><td align="left">&#x000a0;18.5&#x02009;~&#x02009;24.9</td><td char="." align="char">0.96</td><td align="left">0.50&#x02009;~&#x02009;1.84</td><td char="." align="char">0.79</td><td align="left">0.29&#x02009;~&#x02009;2.14</td><td char="." align="char">0.96</td><td align="left">0.50&#x02009;~&#x02009;1.84</td><td char="." align="char">0.65</td><td align="left">0.22&#x02009;~&#x02009;1.86</td></tr><tr><td align="left">&#x000a0;&#x02009;&#x0003e;&#x02009;25</td><td char="." align="char">0.52</td><td align="left">0.21&#x02009;~&#x02009;1.26</td><td char="." align="char">0.37</td><td align="left">0.10&#x02009;~&#x02009;1.36</td><td char="." align="char">0.52</td><td align="left">0.21&#x02009;~&#x02009;1.26</td><td char="." align="char">0.31</td><td align="left">0.08&#x02009;~&#x02009;1.25</td></tr><tr><td align="left">Tumor location</td><td char="." align="char"/><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">&#x000a0;Upper/middle</td><td char="." align="char">1.00</td><td align="left"/><td char="." align="char">1.00</td><td align="left"/><td char="." align="char">1.00</td><td align="left"/><td char="." align="char">1.00</td><td align="left"/></tr><tr><td align="left">&#x000a0;Distal</td><td char="." align="char">0.48</td><td align="left">0.25&#x02009;~&#x02009;0.95</td><td char="." align="char">0.25</td><td align="left">0.10&#x02009;~&#x02009;0.65</td><td char="." align="char">0.48</td><td align="left">0.25&#x02009;~&#x02009;0.95</td><td char="." align="char">0.20</td><td align="left">0.07&#x02009;~&#x02009;0.62</td></tr><tr><td align="left">TNM stage</td><td char="." align="char"/><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">&#x000a0;I-II</td><td char="." align="char">1.00</td><td align="left"/><td char="." align="char">1.00</td><td align="left"/><td char="." align="char">1.00</td><td align="left"/><td char="." align="char">1.00</td><td align="left"/></tr><tr><td align="left">&#x000a0;III-IV</td><td char="." align="char">3.21</td><td align="left">1.83&#x02009;~&#x02009;5.64</td><td char="." align="char">3.49</td><td align="left">1.50&#x02009;~&#x02009;8.12</td><td char="." align="char">3.21</td><td align="left">1.83&#x02009;~&#x02009;5.64</td><td char="." align="char">3.12</td><td align="left">1.24&#x02009;~&#x02009;7.81</td></tr><tr><td align="left">Anastomotic fistula</td><td char="." align="char"/><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">&#x000a0;No</td><td char="." align="char">1.00</td><td align="left"/><td char="." align="char">1.00</td><td align="left"/><td char="." align="char">1.00</td><td align="left"/><td char="." align="char">1.00</td><td align="left"/></tr><tr><td align="left">&#x000a0;Yes</td><td char="." align="char">1.53</td><td align="left">0.55&#x02009;~&#x02009;4.25</td><td char="." align="char">0.66</td><td align="left">0.22&#x02009;~&#x02009;2.03</td><td char="." align="char">1.53</td><td align="left">0.55&#x02009;~&#x02009;4.25</td><td char="." align="char">0.67</td><td align="left">0.20&#x02009;~&#x02009;2.19</td></tr><tr><td align="left">Postoperative infection</td><td char="." align="char"/><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">&#x000a0;No</td><td char="." align="char">1.00</td><td align="left"/><td char="." align="char">1.00</td><td align="left"/><td char="." align="char">1.00</td><td align="left"/><td char="." align="char">1.00</td><td align="left"/></tr><tr><td align="left">&#x000a0;Yes</td><td char="." align="char">0.81</td><td align="left">0.38&#x02009;~&#x02009;1.71</td><td char="." align="char">0.45</td><td align="left">0.17&#x02009;~&#x02009;1.21</td><td char="." align="char">0.81</td><td align="left">0.38&#x02009;~&#x02009;1.71</td><td char="." align="char">0.50</td><td align="left">0.17&#x02009;~&#x02009;1.43</td></tr><tr><td align="left">Invades nerves or vessels</td><td char="." align="char"/><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">&#x000a0;No</td><td char="." align="char">1.00</td><td align="left"/><td char="." align="char">1.00</td><td align="left"/><td char="." align="char">1.00</td><td align="left"/><td char="." align="char">1.00</td><td align="left"/></tr><tr><td align="left">&#x000a0;Yes</td><td char="." align="char">1.94</td><td align="left">0.97&#x02009;~&#x02009;3.86</td><td char="." align="char">2.00</td><td align="left">0.92&#x02009;~&#x02009;4.34</td><td char="." align="char">1.94</td><td align="left">0.97&#x02009;~&#x02009;3.86</td><td char="." align="char">2.14</td><td align="left">0.95&#x02009;~&#x02009;4.83</td></tr><tr><td align="left">hsa-mir-3665-1</td><td char="." align="char"/><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">&#x000a0;&#x02009;&#x02264;&#x02009;50</td><td char="." align="char">1.00</td><td align="left"/><td char="." align="char">1.00</td><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">&#x000a0;&#x02009;&#x0003e;&#x02009;50</td><td char="." align="char">1.63</td><td align="left">0.65&#x02009;~&#x02009;4.10</td><td char="." align="char">3.89</td><td align="left">1.11&#x02009;~&#x02009;13.55</td><td char="." align="char"/><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">hsa-mir-3665-2</td><td char="." align="char"/><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">&#x000a0;&#x02009;&#x02264;&#x02009;50</td><td char="." align="char"/><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char">1.00</td><td align="left"/><td char="." align="char">1.00</td><td align="left"/></tr><tr><td align="left">&#x000a0;&#x02009;&#x0003e;&#x02009;50</td><td char="." align="char"/><td align="left"/><td char="." align="char"/><td align="left"/><td char="." align="char">0.87</td><td align="left">0.46&#x02009;~&#x02009;1.63</td><td char="." align="char">1.27</td><td align="left">0.54&#x02009;~&#x02009;3.00</td></tr></tbody></table><table-wrap-foot><p>*Adjusted for sex, age, BMI, tumor location, TNM stage, anastomotic fistula, postoperative infection, invades nerves or vessels, hsa-mir-3665-1/hsa-mir-3665-2</p></table-wrap-foot></table-wrap></p><p id="Par41">Moreover, a nomogram incorporating the hsa-miR-3665-1 methylation level and clinical factors was constructed to predict OS in ESCC patients (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). The predictive model was virtually presented in the form of a nomogram (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>) in the training test and was validated with the C-indices of the novel nomogram being 0.748 and 0.751, respectively, reflecting the good discrimination ability of the model. The calibration plot demonstrated that the predicted overall survival probabilities corresponded closely with the observed probabilities (Fig. <xref rid="MOESM4" ref-type="media">S4</xref>).<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Nomogram predicting the hsa-miR-3665&#x02013;1 methylation level and clinical factors for patients with ESCC in the training (<bold>A</bold>) and validation sets (<bold>B</bold>)</p></caption><graphic xlink:href="10147_2024_2656_Fig3_HTML" id="MO3"/></fig></p></sec></sec><sec id="Sec20"><title>Discussion</title><p id="Par42">MiRNAs are currently implicated in various biological processes [<xref ref-type="bibr" rid="CR23">23</xref>]. The identification of miRNA promoter methylation will not only enhance our understanding of their role in regulating miRNA expression but also provide prognostic biomarkers for different cancers. In our study, we found that ESCC with a high methylation level of hsa-miR-3665 had a significantly worse prognosis, suggesting that aberrant promoter methylation of hsa-miR-3665 plays a crucial role in ESCC.</p><p id="Par43">Many potential cancer biomarkers for diagnosis and prognosis have been proposed based on miRNA expression levels [<xref ref-type="bibr" rid="CR24">24</xref>]. However, the methylation state of miRNAs might potentially alter their stability and target recognition, and it might be better than miRNA as a biomarker [<xref ref-type="bibr" rid="CR25">25</xref>]. Accumulating evidence has indicated that miRNA promoter methylation is related to the progression of cancers and may serve as a potential candidate for predicting the progression of different types of cancers [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. Vera et al. found that the methylation status of the miR-7 promoter was associated with poorer prognosis in ovarian cancer patients [<xref ref-type="bibr" rid="CR28">28</xref>]. The hypomethylation of the chromosome 19 microRNA cluster promoter has been declared to be significant for the prognosis evaluation of hepatocellular carcinoma [<xref ref-type="bibr" rid="CR26">26</xref>]. Meanwhile, Tian et al. [<xref ref-type="bibr" rid="CR12">12</xref>] showed that the overall survival of ESCC patients with promoter hypermethylation of miR-124-1 (<italic>HR</italic>&#x02009;=&#x02009;3.245) or miR-124-3 (<italic>HR</italic>&#x02009;=&#x02009;3.539) was significantly shorter than other ESCC patients and Liu et al. [<xref ref-type="bibr" rid="CR16">16</xref>] revealed the promoter hypermethylation of miR-203a (<italic>HR</italic>&#x02009;=&#x02009;1.794) were independently associated with survival of ESCC patients by cox multivariate analysis. In this study, we screened miRNAs with CpG islands from the human miRNA database, which involves a comprehensive assessment of miRNAs. By comprehensive screening of human miRNA promoter methylation, our results showed for the first time that hsa-miR-3665 was epigenetically regulated in ESCC cells, and hypermethylation of the hsa-miR-3665 promoter was associated with a poor prognosis in ESCC, which suggested that it might be an important biomarker for ESCC prognosis.</p><p id="Par44">Promoter hypermethylation of hsa-miR-3665 in ESCC includes hsa-miR-3665-1 and hsa-miR-3665-2. Initial chi-square analysis suggested a potential association between hsa-miR-3665-2 and the TNM stage. However, subsequent multivariate logistic regression analysis, accounting for potential confounding factors, revealed that this association lacked statistical significance. This suggests that the noted correlation might be influenced by confounding effects. Interestingly, after adjusting for covariates, including the TNM stage, multivariate Cox regression analysis demonstrated that the methylation status of hsa-miR-3665-1 is significantly associated with poor prognosis in ESCC. This contrasts with hsa-miR-3665-2, whose promoter region contains fewer CpG sites. This structural difference may explain why the methylation status of hsa-miR-3665-2 appears unrelated to ESCC prognosis.</p><p id="Par45">Although studies have indicated that hsa-miR-3665 dysregulation is closely related to various cancers, the regulatory mechanism and function of hsa-miR-3665 remain elusive. Kilpinen et al. [<xref ref-type="bibr" rid="CR29">29</xref>] pointed out that aberrant hsa-miR-3665 expression was involved in immune regulation and the cell cycle, and was associated with age-related bone marrow mesenchymal stromal cells. To further explore its function, the target genes of hsa-miR-3665 identified in this study underwent GO and KEGG pathway enrichment analysis. GO enrichment analysis revealed functions in protein transport, cell adhesion, transcription regulator activity, and signal transduction. KEGG pathway analyses revealed that these target genes participate in the regulation of MAPK signaling pathway, RAS signaling pathway and signaling pathways regulating pluripotency of stem cells. The MAPK and RAS signaling pathway play an important role in tumorigenesis and progression by activating related kinases to regulate cell growth, differentiation, proliferation, apoptosis and migration functions [<xref ref-type="bibr" rid="CR30">30</xref>]. Our results showed that hsa-miR-3665 promoter methylation might affect cell progression in ESCC through MAPK and RAS signaling pathway to associate with the prognosis of ESCC patients. This also implies that hsa-miR-3665 promoter methylation can be used to predict the prognosis of ESCC patients. Nomograms, which combine various clinical factors to predict survival, have been considered useful tools in ESCC [<xref ref-type="bibr" rid="CR31">31</xref>]. Nevertheless, few studies have analysed the relationship between miRNA promoter methylation and ESCC prognosis by using nomograms. We showed that by incorporating the hsa-miR-3665 methylation level and clinical factors, the nomogram presented good performance for training and validation tests, with C-indices of 0.748 and 0.751, suggesting a better ability to predict the ESCC outcome.</p><p id="Par46">There are several limitations of our study. First, although we validated our results in ESCC tissues, those results were not further validated by experiments such as functional experiments in vitro. It is important to research the potential regulatory mechanisms of hsa-miR-3665 promoter methylation in the progression of ESCC in vitro. In addition, further studies are needed to validate our results with larger samples.</p></sec><sec id="Sec21"><title>Conclusions</title><p id="Par47">In summary, we found that a high hsa-miR-3665 promoter methylation level was associated with worse progression in ESCC. Our results suggest that hsa-miR-3665 promoter methylation may be a potential biomarker for predicting the progression of ESCC.</p></sec><sec id="Sec22" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="10147_2024_2656_MOESM1_ESM.pdf"><caption><p>Supplementary file1 (PDF 188 KB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="10147_2024_2656_MOESM2_ESM.pdf"><caption><p>Supplementary file2 (PDF 175 KB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="10147_2024_2656_MOESM3_ESM.pdf"><caption><p>Supplementary file3 (PDF 255 KB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="10147_2024_2656_MOESM4_ESM.pdf"><caption><p>Supplementary file4 (PDF 115 KB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="10147_2024_2656_MOESM5_ESM.docx"><caption><p>Supplementary file5 (DOCX 36 KB)</p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ESCC</term><def><p id="Par5">Esophageal squamous cell carcinoma</p></def></def-item><def-item><term>EAC</term><def><p id="Par6">Esophageal adenocarcinoma</p></def></def-item><def-item><term>EBI</term><def><p id="Par7">European Bioinformatics Institute</p></def></def-item><def-item><term>TNM</term><def><p id="Par8">Tumor node metastasis</p></def></def-item><def-item><term>DAC</term><def><p id="Par9">5-Aza-2&#x002b9; -deoxycytidine</p></def></def-item><def-item><term>RQ</term><def><p id="Par10">Relative quantification</p></def></def-item><def-item><term>qPCR</term><def><p id="Par11">Quantitative real-time PCR</p></def></def-item><def-item><term>MS-HRM</term><def><p id="Par12">Methylation-specific high resolution melting</p></def></def-item><def-item><term>GO</term><def><p id="Par13">Gene ontology</p></def></def-item><def-item><term>KEGG</term><def><p id="Par14">Kyoto Encyclopedia of Genes and Genomes</p></def></def-item><def-item><term>OS</term><def><p id="Par15">Overall survival</p></def></def-item><def-item><term>HR</term><def><p id="Par16">Hazard ratio</p></def></def-item><def-item><term>95% CI</term><def><p id="Par17">95% Confidence interval</p></def></def-item><def-item><term>C-index</term><def><p id="Par18">Concordance index</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Jinsong Zhou and Shuang Liu have contributed equally to this work.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank Zhangzhou Affiliated Hospital of Fujian Medical University for data collection.</p></ack><notes notes-type="author-contribution"><title>Authors' contributions</title><p>HZJ conceived of the study, participated in its design and reviewed the manuscript. ZJS, and LZ designed the study, performed the data analysis and drafted the manuscript. ZQY, LS, and LYL performed drafted the manuscript. RF, LS, ZJW and SJY carried out the clinical sample collection and drafted the part of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was supported by the Scientific and Technological Innovation Joint Capital Projects of Fujian Province (No.2020Y9018), Natural Science Foundation of Fujian Province (No. 2021J01726), Natural Science Foundation of Fujian Province (No. 2021J01733), Central government-led local science and technology development special project (No. 2020L3009 and No. 2019L3006).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par48">The authors have no conflict of interest to declare.</p></notes><notes id="FPar2"><title>Ethics approval and consent to participate</title><p id="Par49">This study described has been carried out in accordance with the Declaration of Helsinki for experiments involving humans. This study was approved by the Institutional Review Boards of Fujian Medical University (NO. 2011052), and all participants signed informed consent forms.</p></notes><notes id="FPar3"><title>Consent for publication</title><p id="Par50">Not applicable.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>H</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><year>2021</year><volume>71</volume><fpage>209</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.3322/caac.21660</pub-id><pub-id pub-id-type="pmid">33538338</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209&#x02013;249. 10.3322/caac.21660<pub-id pub-id-type="pmid">33538338</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Zheng</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Cancer incidence and mortality in China in 2013: an analysis based on urbanization level</article-title><source>Chin J Cancer Res</source><year>2017</year><volume>29</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.21147/j.issn.1000-9604.2017.01.01</pub-id><pub-id pub-id-type="pmid">28373748</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Chen W, Zheng R, Zhang S et al (2017) Cancer incidence and mortality in China in 2013: an analysis based on urbanization level. Chin J Cancer Res 29:1&#x02013;10<pub-id pub-id-type="pmid">28373748</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Abnet</surname><given-names>CC</given-names></name><name><surname>Arnold</surname><given-names>M</given-names></name><name><surname>Wei</surname><given-names>W-Q</given-names></name></person-group><article-title>Epidemiology of esophageal squamous cell carcinoma</article-title><source>Gastroenterology</source><year>2018</year><volume>154</volume><fpage>360</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2017.08.023</pub-id><pub-id pub-id-type="pmid">28823862</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Abnet CC, Arnold M, Wei W-Q (2018) Epidemiology of esophageal squamous cell carcinoma. Gastroenterology 154:360&#x02013;373. 10.1053/j.gastro.2017.08.023<pub-id pub-id-type="pmid">28823862</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Baba</surname><given-names>Y</given-names></name><name><surname>Yoshida</surname><given-names>N</given-names></name><name><surname>Kinoshita</surname><given-names>K</given-names></name><etal/></person-group><article-title>Clinical and prognostic features of patients with esophageal cancer and multiple primary cancers: a retrospective single-institution study</article-title><source>Ann Surg</source><year>2018</year><volume>267</volume><fpage>478</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1097/SLA.0000000000002118</pub-id><pub-id pub-id-type="pmid">28151796</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Baba Y, Yoshida N, Kinoshita K et al (2018) Clinical and prognostic features of patients with esophageal cancer and multiple primary cancers: a retrospective single-institution study. Ann Surg 267:478&#x02013;483. 10.1097/SLA.0000000000002118<pub-id pub-id-type="pmid">28151796</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W-W</given-names></name><name><surname>Zhao</surname><given-names>Z-H</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><etal/></person-group><article-title>MicroRNA-134 prevents the progression of esophageal squamous cell carcinoma via the PLXNA1-mediated MAPK signalling pathway</article-title><source>EBioMedicine</source><year>2019</year><volume>46</volume><fpage>66</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2019.07.050</pub-id><pub-id pub-id-type="pmid">31383552</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Wang W-W, Zhao Z-H, Wang L et al (2019) MicroRNA-134 prevents the progression of esophageal squamous cell carcinoma via the PLXNA1-mediated MAPK signalling pathway. EBioMedicine 46:66&#x02013;78. 10.1016/j.ebiom.2019.07.050<pub-id pub-id-type="pmid">31383552</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A six-microRNA risk score model predicts prognosis in esophageal squamous cell carcinoma</article-title><source>J Cell Physiol</source><year>2019</year><volume>234</volume><fpage>6810</fpage><lpage>6819</lpage><pub-id pub-id-type="doi">10.1002/jcp.27429</pub-id><pub-id pub-id-type="pmid">30387125</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Mao Y, Fu Z, Zhang Y et al (2019) A six-microRNA risk score model predicts prognosis in esophageal squamous cell carcinoma. J Cell Physiol 234:6810&#x02013;6819. 10.1002/jcp.27429<pub-id pub-id-type="pmid">30387125</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Mattei</surname><given-names>AL</given-names></name><name><surname>Bailly</surname><given-names>N</given-names></name><name><surname>Meissner</surname><given-names>A</given-names></name></person-group><article-title>DNA methylation: a historical perspective</article-title><source>Trends Genet</source><year>2022</year><volume>38</volume><fpage>676</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.1016/j.tig.2022.03.010</pub-id><pub-id pub-id-type="pmid">35504755</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Mattei AL, Bailly N, Meissner A (2022) DNA methylation: a historical perspective. Trends Genet 38:676&#x02013;707. 10.1016/j.tig.2022.03.010<pub-id pub-id-type="pmid">35504755</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Peng</surname><given-names>D</given-names></name><etal/></person-group><article-title>A novel strategy for the diagnosis, prognosis, treatment, and chemoresistance of hepatocellular carcinoma: DNA methylation</article-title><source>Med Res Rev</source><year>2020</year><volume>40</volume><fpage>1973</fpage><lpage>2018</lpage><pub-id pub-id-type="doi">10.1002/med.21696</pub-id><pub-id pub-id-type="pmid">32525219</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Liu A, Wu Q, Peng D et al (2020) A novel strategy for the diagnosis, prognosis, treatment, and chemoresistance of hepatocellular carcinoma: DNA methylation. Med Res Rev 40:1973&#x02013;2018. 10.1002/med.21696<pub-id pub-id-type="pmid">32525219</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Teng</surname><given-names>H</given-names></name><name><surname>Xue</surname><given-names>M</given-names></name><name><surname>Liang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Inter- and intratumor DNA methylation heterogeneity associated with lymph node metastasis and prognosis of esophageal squamous cell carcinoma</article-title><source>Theranostics</source><year>2020</year><volume>10</volume><fpage>3035</fpage><lpage>3048</lpage><pub-id pub-id-type="doi">10.7150/thno.42559</pub-id><pub-id pub-id-type="pmid">32194853</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Teng H, Xue M, Liang J et al (2020) Inter- and intratumor DNA methylation heterogeneity associated with lymph node metastasis and prognosis of esophageal squamous cell carcinoma. Theranostics 10:3035&#x02013;3048. 10.7150/thno.42559<pub-id pub-id-type="pmid">32194853</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Aghdam</surname><given-names>SG</given-names></name><name><surname>Ebrazeh</surname><given-names>M</given-names></name><name><surname>Hemmatzadeh</surname><given-names>M</given-names></name><etal/></person-group><article-title>The role of microRNAs in prostate cancer migration, invasion, and metastasis</article-title><source>J Cell Physiol</source><year>2019</year><volume>234</volume><fpage>9927</fpage><lpage>9942</lpage><pub-id pub-id-type="doi">10.1002/jcp.27948</pub-id><pub-id pub-id-type="pmid">30536403</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Aghdam SG, Ebrazeh M, Hemmatzadeh M et al (2019) The role of microRNAs in prostate cancer migration, invasion, and metastasis. J Cell Physiol 234:9927&#x02013;9942. 10.1002/jcp.27948<pub-id pub-id-type="pmid">30536403</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Goradel</surname><given-names>NH</given-names></name><name><surname>Mohammadi</surname><given-names>N</given-names></name><name><surname>Haghi-Aminjan</surname><given-names>H</given-names></name><etal/></person-group><article-title>Regulation of tumor angiogenesis by microRNAs: state of the art</article-title><source>J Cell Physiol</source><year>2019</year><volume>234</volume><fpage>1099</fpage><lpage>1110</lpage><pub-id pub-id-type="doi">10.1002/jcp.27051</pub-id><pub-id pub-id-type="pmid">30070704</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Goradel NH, Mohammadi N, Haghi-Aminjan H et al (2019) Regulation of tumor angiogenesis by microRNAs: state of the art. J Cell Physiol 234:1099&#x02013;1110. 10.1002/jcp.27051<pub-id pub-id-type="pmid">30070704</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Hypermethylation-mediated inactivation of miR-124 predicts poor prognosis and promotes tumor growth at least partially through targeting EZH2/H3K27me3 in ESCC</article-title><source>Clin Exp Metastasis</source><year>2019</year><volume>36</volume><fpage>381</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1007/s10585-019-09974-1</pub-id><pub-id pub-id-type="pmid">31197517</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Tian Z, Li Z, Zhu Y et al (2019) Hypermethylation-mediated inactivation of miR-124 predicts poor prognosis and promotes tumor growth at least partially through targeting EZH2/H3K27me3 in ESCC. Clin Exp Metastasis 36:381&#x02013;391. 10.1007/s10585-019-09974-1<pub-id pub-id-type="pmid">31197517</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>DNMT1 recruited by EZH2-mediated silencing of miR-484 contributes to the malignancy of cervical cancer cells through MMP14 and HNF1A</article-title><source>Clin Epigenetics</source><year>2019</year><volume>11</volume><fpage>186</fpage><pub-id pub-id-type="doi">10.1186/s13148-019-0786-y</pub-id><pub-id pub-id-type="pmid">31810492</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Hu Y, Wu F, Liu Y et al (2019) DNMT1 recruited by EZH2-mediated silencing of miR-484 contributes to the malignancy of cervical cancer cells through MMP14 and HNF1A. Clin Epigenetics 11:186. 10.1186/s13148-019-0786-y<pub-id pub-id-type="pmid">31810492</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><etal/></person-group><article-title>Promoter methylation-regulated miR-145-5p inhibits laryngeal squamous cell carcinoma progression by targeting FSCN1</article-title><source>Mol Ther</source><year>2019</year><volume>27</volume><fpage>365</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2018.09.018</pub-id><pub-id pub-id-type="pmid">30341010</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Gao W, Zhang C, Li W et al (2019) Promoter methylation-regulated miR-145-5p inhibits laryngeal squamous cell carcinoma progression by targeting FSCN1. Mol Ther 27:365&#x02013;379. 10.1016/j.ymthe.2018.09.018<pub-id pub-id-type="pmid">30341010</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Torres-Ferreira</surname><given-names>J</given-names></name><name><surname>Ramalho-Carvalho</surname><given-names>J</given-names></name><name><surname>Gomez</surname><given-names>A</given-names></name><etal/></person-group><article-title>MiR-193b promoter methylation accurately detects prostate cancer in urine sediments and miR-34b/c or miR-129-2 promoter methylation define subsets of clinically aggressive tumors</article-title><source>Mol Cancer</source><year>2017</year><volume>16</volume><fpage>26</fpage><pub-id pub-id-type="doi">10.1186/s12943-017-0604-0</pub-id><pub-id pub-id-type="pmid">28143614</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Torres-Ferreira J, Ramalho-Carvalho J, Gomez A et al (2017) MiR-193b promoter methylation accurately detects prostate cancer in urine sediments and miR-34b/c or miR-129-2 promoter methylation define subsets of clinically aggressive tumors. Mol Cancer 16:26. 10.1186/s12943-017-0604-0<pub-id pub-id-type="pmid">28143614</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>Z</given-names></name><name><surname>Liang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Methylation-mediated repression of potential tumor suppressor miR-203a and miR-203b contributes to esophageal squamous cell carcinoma development</article-title><source>Tumour Biol</source><year>2016</year><volume>37</volume><fpage>5621</fpage><lpage>5632</lpage><pub-id pub-id-type="doi">10.1007/s13277-015-4432-9</pub-id><pub-id pub-id-type="pmid">26577858</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Liu Y, Dong Z, Liang J et al (2016) Methylation-mediated repression of potential tumor suppressor miR-203a and miR-203b contributes to esophageal squamous cell carcinoma development. Tumour Biol 37:5621&#x02013;5632. 10.1007/s13277-015-4432-9<pub-id pub-id-type="pmid">26577858</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>B</given-names></name><name><surname>Treadwell</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><etal/></person-group><article-title>Large-scale expression analysis reveals distinct microRNA profiles at different stages of human neurodevelopment</article-title><source>PLoS ONE</source><year>2010</year><pub-id pub-id-type="doi">10.1371/journal.pone.0011109</pub-id><pub-id pub-id-type="pmid">21209956</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Smith B, Treadwell J, Zhang D et al (2010) Large-scale expression analysis reveals distinct microRNA profiles at different stages of human neurodevelopment. PLoS ONE. 10.1371/journal.pone.0011109<pub-id pub-id-type="pmid">21209956</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Asahchop</surname><given-names>EL</given-names></name><name><surname>Akinwumi</surname><given-names>SM</given-names></name><name><surname>Branton</surname><given-names>WG</given-names></name><etal/></person-group><article-title>Plasma microRNA profiling predicts HIV-associated neurocognitive disorder</article-title><source>AIDS</source><year>2016</year><volume>30</volume><fpage>2021</fpage><lpage>2031</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000001160</pub-id><pub-id pub-id-type="pmid">27191977</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Asahchop EL, Akinwumi SM, Branton WG et al (2016) Plasma microRNA profiling predicts HIV-associated neurocognitive disorder. AIDS 30:2021&#x02013;2031. 10.1097/QAD.0000000000001160<pub-id pub-id-type="pmid">27191977</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Manni</surname><given-names>E</given-names></name><name><surname>Jeffery</surname><given-names>N</given-names></name><name><surname>Chambers</surname><given-names>D</given-names></name><etal/></person-group><article-title>An evaluation of the role of miR-361-5p in senescence and systemic ageing</article-title><source>Exp Gerontol</source><year>2023</year><pub-id pub-id-type="doi">10.1016/j.exger.2023.112127</pub-id><pub-id pub-id-type="pmid">36804517</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Manni E, Jeffery N, Chambers D et al (2023) An evaluation of the role of miR-361-5p in senescence and systemic ageing. Exp Gerontol. 10.1016/j.exger.2023.112127<pub-id pub-id-type="pmid">36804517</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Chakraborty</surname><given-names>S</given-names></name><name><surname>Nath</surname><given-names>D</given-names></name></person-group><article-title>A study on microRNAs targeting the genes overexpressed in lung cancer and their codon usage patterns</article-title><source>Mol Biotechnol</source><year>2022</year><volume>64</volume><fpage>1095</fpage><lpage>1119</lpage><pub-id pub-id-type="doi">10.1007/s12033-022-00491-3</pub-id><pub-id pub-id-type="pmid">35435592</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Chakraborty S, Nath D (2022) A study on microRNAs targeting the genes overexpressed in lung cancer and their codon usage patterns. Mol Biotechnol 64:1095&#x02013;1119. 10.1007/s12033-022-00491-3<pub-id pub-id-type="pmid">35435592</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Ni</surname><given-names>J</given-names></name><name><surname>Liang</surname><given-names>S</given-names></name><name><surname>Shan</surname><given-names>B</given-names></name><etal/></person-group><article-title>Methylation-associated silencing of miR-638 promotes endometrial carcinoma progression by targeting MEF2C</article-title><source>Int J Mol Med</source><year>2020</year><volume>45</volume><fpage>1753</fpage><lpage>1770</lpage><pub-id pub-id-type="doi">10.3892/ijmm.2020.4540</pub-id><pub-id pub-id-type="pmid">32186750</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Ni J, Liang S, Shan B et al (2020) Methylation-associated silencing of miR-638 promotes endometrial carcinoma progression by targeting MEF2C. Int J Mol Med 45:1753&#x02013;1770. 10.3892/ijmm.2020.4540<pub-id pub-id-type="pmid">32186750</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Yin</surname><given-names>R</given-names></name><etal/></person-group><article-title>A nomogram to predict overall survival of patients with early stage non-small cell lung cancer</article-title><source>J Thorac Dis</source><year>2019</year><volume>11</volume><fpage>5407</fpage><lpage>5416</lpage><pub-id pub-id-type="doi">10.21037/jtd.2019.11.53</pub-id><pub-id pub-id-type="pmid">32030259</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Zhang J, Fan J, Yin R et al (2019) A nomogram to predict overall survival of patients with early stage non-small cell lung cancer. J Thorac Dis 11:5407&#x02013;5416<pub-id pub-id-type="pmid">32030259</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Gomez</surname><given-names>EC</given-names></name><name><surname>Chalabi-Dchar</surname><given-names>M</given-names></name><etal/></person-group><article-title>Integrated analysis of mRNA and miRNA expression in HeLa cells expressing low levels of Nucleolin</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>9017</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-09353-4</pub-id><pub-id pub-id-type="pmid">28827664</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Kumar S, Gomez EC, Chalabi-Dchar M et al (2017) Integrated analysis of mRNA and miRNA expression in HeLa cells expressing low levels of Nucleolin. Sci Rep 7:9017. 10.1038/s41598-017-09353-4<pub-id pub-id-type="pmid">28827664</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>B</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Cai</surname><given-names>Q</given-names></name><etal/></person-group><article-title>miRNA-based biomarkers, therapies, and resistance in Cancer</article-title><source>Int J Biol Sci</source><year>2020</year><volume>16</volume><fpage>2628</fpage><lpage>2647</lpage><pub-id pub-id-type="doi">10.7150/ijbs.47203</pub-id><pub-id pub-id-type="pmid">32792861</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">He B, Zhao Z, Cai Q et al (2020) miRNA-based biomarkers, therapies, and resistance in Cancer. Int J Biol Sci 16:2628&#x02013;2647. 10.7150/ijbs.47203<pub-id pub-id-type="pmid">32792861</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Konno</surname><given-names>M</given-names></name><name><surname>Koseki</surname><given-names>J</given-names></name><name><surname>Asai</surname><given-names>A</given-names></name><etal/></person-group><article-title>Distinct methylation levels of mature microRNAs in gastrointestinal cancers</article-title><source>Nat Commun</source><year>2019</year><volume>10</volume><fpage>3888</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-11826-1</pub-id><pub-id pub-id-type="pmid">31467274</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Konno M, Koseki J, Asai A et al (2019) Distinct methylation levels of mature microRNAs in gastrointestinal cancers. Nat Commun 10:3888. 10.1038/s41467-019-11826-1<pub-id pub-id-type="pmid">31467274</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Rui</surname><given-names>T</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>The chromosome 19 microRNA cluster, regulated by promoter hypomethylation, is associated with tumour burden and poor prognosis in patients with hepatocellular carcinoma</article-title><source>J Cell Physiol</source><year>2020</year><volume>235</volume><fpage>6103</fpage><lpage>6112</lpage><pub-id pub-id-type="doi">10.1002/jcp.29538</pub-id><pub-id pub-id-type="pmid">31975381</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Rui T, Xu S, Zhang X et al (2020) The chromosome 19 microRNA cluster, regulated by promoter hypomethylation, is associated with tumour burden and poor prognosis in patients with hepatocellular carcinoma. J Cell Physiol 235:6103&#x02013;6112. 10.1002/jcp.29538<pub-id pub-id-type="pmid">31975381</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Epigenetic silencing of microRNA-204 by Helicobacter pylori augments the NF-&#x003ba;B signaling pathway in gastric cancer development and progression</article-title><source>Carcinogenesis</source><year>2020</year><volume>41</volume><fpage>430</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgz143</pub-id><pub-id pub-id-type="pmid">31873718</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Chen P, Guo H, Wu X et al (2020) Epigenetic silencing of microRNA-204 by Helicobacter pylori augments the NF-&#x003ba;B signaling pathway in gastric cancer development and progression. Carcinogenesis 41:430&#x02013;441. 10.1093/carcin/bgz143<pub-id pub-id-type="pmid">31873718</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Vera</surname><given-names>O</given-names></name><name><surname>Jimenez</surname><given-names>J</given-names></name><name><surname>Pernia</surname><given-names>O</given-names></name><etal/></person-group><article-title>DNA methylation of miR-7 is a mechanism involved in platinum response through MAFG overexpression in cancer cells</article-title><source>Theranostics</source><year>2017</year><volume>7</volume><fpage>4118</fpage><lpage>4134</lpage><pub-id pub-id-type="doi">10.7150/thno.20112</pub-id><pub-id pub-id-type="pmid">29158814</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Vera O, Jimenez J, Pernia O et al (2017) DNA methylation of miR-7 is a mechanism involved in platinum response through MAFG overexpression in cancer cells. Theranostics 7:4118&#x02013;4134. 10.7150/thno.20112<pub-id pub-id-type="pmid">29158814</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Kilpinen</surname><given-names>L</given-names></name><name><surname>Parmar</surname><given-names>A</given-names></name><name><surname>Greco</surname><given-names>D</given-names></name><etal/></person-group><article-title>Expansion induced microRNA changes in bone marrow mesenchymal stromal cells reveals interplay between immune regulation and cell cycle</article-title><source>Aging (Albany NY)</source><year>2016</year><volume>8</volume><fpage>2799</fpage><lpage>2813</lpage><pub-id pub-id-type="doi">10.18632/aging.101088</pub-id><pub-id pub-id-type="pmid">27852979</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Kilpinen L, Parmar A, Greco D et al (2016) Expansion induced microRNA changes in bone marrow mesenchymal stromal cells reveals interplay between immune regulation and cell cycle. Aging (Albany NY) 8:2799&#x02013;2813<pub-id pub-id-type="pmid">27852979</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Santarpia</surname><given-names>L</given-names></name><name><surname>Lippman</surname><given-names>SM</given-names></name><name><surname>El-Naggar</surname><given-names>AK</given-names></name></person-group><article-title>Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy</article-title><source>Expert Opin Ther Targets</source><year>2012</year><volume>16</volume><fpage>103</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1517/14728222.2011.645805</pub-id><pub-id pub-id-type="pmid">22239440</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Santarpia L, Lippman SM, El-Naggar AK (2012) Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets 16:103&#x02013;119. 10.1517/14728222.2011.645805<pub-id pub-id-type="pmid">22239440</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Nomogram to predict overall survival for thoracic esophageal squamous cell carcinoma patients after radical esophagectomy</article-title><source>Ann Surg Oncol</source><year>2019</year><volume>26</volume><fpage>2890</fpage><lpage>2898</lpage><pub-id pub-id-type="doi">10.1245/s10434-019-07393-w</pub-id><pub-id pub-id-type="pmid">31183641</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Deng W, Zhang W, Yang J et al (2019) Nomogram to predict overall survival for thoracic esophageal squamous cell carcinoma patients after radical esophagectomy. Ann Surg Oncol 26:2890&#x02013;2898. 10.1245/s10434-019-07393-w<pub-id pub-id-type="pmid">31183641</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>